MK2 inhibitors and uses thereof
The present invention provides compounds, compositions thereof, and methods of using the same.
1. A compound of formula XVI:
or a pharmaceutically acceptable salt thereof, wherein:
T is —NH— or —O—;
each R is independently hydrogen or an optionally substituted C 1-6 aliphatic, or:
two R groups on the same nitrogen are taken together with the nitrogen to form a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur;
R 1 is methyl;
R 2 is halogen, —CN, —SR y , —S(O)R y , —SO 2 R y , —OSO 2 R y , —OC(O)R y , or —OP(O) 2 OR y ;
each R y is independently selected from optionally substituted C 1-6 aliphatic or optionally substituted phenyl.
2. The compound according to claim 1 , wherein -T- is —O—.
3. The compound according to claim 1 , wherein R 2 is halogen.
4. The compound according to claim 3 wherein R 2 is chloro.
5. The compound according to claim 1 , wherein each R is independently hydrogen or optionally substituted C 1-6 aliphatic.
6. The compound according to claim 5 , wherein each R is independently hydrogen or C 1-6 aliphatic substituted with oxo, halogen, —CN, —(CH 2 ) 0-4 R ∘ , —(CH 2 ) 0-4 OR ∘ , or —(CH 2 ) 0-4 S(O) 2 R ∘ , wherein R ∘ is C 1-6 aliphatic.
7. A pharmaceutically acceptable composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
8. A compound of formula XX:
or a pharmaceutically acceptable salt thereof, wherein:
T is —NH— or —O—;
R is independently hydrogen or an optionally substituted C 1-6 aliphatic;
R 1 is methyl;
R 2 is halogen, —CN, —SR y , —S(O)R y , —SO 2 R y , —OSO 2 R y , —OC(O)R y , or —OP(O) 2 OR y ;
each R y is independently selected from optionally substituted C 1-6 aliphatic or optionally substituted phenyl.
9. The compound according to claim 8 , wherein -T- is —O—.
10. The compound according to claim 8 , wherein R 2 is halogen.
11. The compound according to claim 10 wherein R 2 is chloro.
12. The compound according to claim 8 , wherein R is optionally substituted C 1-6 aliphatic.
13. The compound according to claim 12 , wherein R is C 1-6 aliphatic substituted with oxo, halogen, —CN, —(CH 2 ) 0-4 R ∘ , —(CH 2 ) 0-4 OR ∘ , or —(CH 2 ) 0-4 S(O) 2 R ∘ , wherein R ∘ is C 1-6 aliphatic.
14. The compound according to claim 13 , wherein R is ethyl substituted with oxo, halogen, —CN, —(CH 2 ) 0-4 R ∘ , —(CH 2 ) 0-4 OR ∘ , or —(CH 2 ) 0-4 S(O) 2 R ∘ , wherein R ∘ is C 1-6 aliphatic.
15. A pharmaceutically acceptable composition comprising the compound according to claim 8 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.